ICE Bioscience

As we step into 2025, let's embrace the opportunities ahead with hope and excitement. The journey ahead is filled with new possibilities, and we truly believe that amazing things are just around the corner. 🌟 May this year bring growth, success, and happiness to all. #HappyNewYear #2025 #NewBeginnings #SuccessAhead #Grateful #LookingForward

Wishing you a joyful holiday season filled with warmth, laughter, and success. Happy Holidays from all of us at ICE Bioscience!🎉✨

As this week is the final week of 2024, let’s wrap up our poster review series with one of the posters we presented at ENA 2024 to kick off the journey into 2025! This poster highlights the application of 2D and 3D cell panel screening platforms to accelerate RAS-targeted drug discovery, addressing critical challenges in treating KRAS-mutated cancers. KRAS mutation is a core driver of many cancers and is closely associated with tumor aggressiveness and poor prognosis, making targeted KRAS therapy an important breakthrough in cancer treatment. Several companies, such as Erasca, Inc., Redx Pharma and Revolution Medicines, are advancing the development of KRAS-targeted drugs and have achieved significant progress.. However, the complexity of the RAS signaling pathway and drug resistance make treatment challenging. To address these issues, we have established a 2D and 3D Cell Panel screening platform. In our efforts, we have: ✅ICE KRAS Cell Panel Platform: Developed the ICECP™ Pan KRAS cell panel with 40 cell lines across 11 cancer types, utilizing 2D and 3D CellTiter-Glo for screening. ✅ KRAS Resistant Cell Lines: viability assays for various KRAS inhibitors, demonstrating the ability of new compounds to overcome drug resistance. ✅ KRAS Signaling Pathway-Phospho-ERK Panel: Established pERK detection assays for precise analysis of pathway inhibition. ✅ Bioinformatics Analysis for KRAS Cell Panel: Conducted analyses to identify resistance mechanisms and genomic signatures linked to therapeutic response. Explore our latest poster here. 👉 https://lnkd.in/ghjY8K_v #KRAS #RAS #Mutation #KRASCellPanel #ENA2024 #2Dcellmodel #3Dcellmodel #PhosphoERK #pERK #Bioinformatics #DrugResistance #DrugScreening 

TYK2 (tyrosine kinase 2) is an important factor in the regulation of immune response and inflammation, and its dysfunction is associated with a variety of inflammatory diseases. Investigating the role of TYK2 in cytokine signaling is critical for the development of targeted therapies for these diseases. Currently, several companies like Allorion Therapeutics, Sudo Biosciences and Priovant Therapeutics are advancing the development of TYK2-targeted inhibitors for the treatment of autoimmune and inflammatory diseases. In response to TYK2 drug discovery, we offer: 🔸 ADP-Glo Assay: Assesses TYK2 kinase activity by measuring ATP hydrolysis to ADP, providing insight into the effectiveness of inhibitors. 🔸 Fluorescence Polarization (FP) Assay: Evaluates the binding affinity of inhibitors to the TYK2 JH2 domain, assessing molecular binding interactions. 🔸 Reporter Gene Assay: Measures the inhibition of TYK2 signaling pathways by assessing cytokine-mediated STAT phosphorylation in a variety of cell models.  🔸 In vitro Functional Assays: Utilize ELISA, AlphaLISA, and flow cytometry to analyze STAT phosphorylation levels and cytokine secretion, validating the immune-modulatory effects of TYK2 inhibitor Discover how our assays can enhance your efficiency in TYK2-targeted therapy research 👉 https://lnkd.in/gU9sC3NE #TYK2 #JAKS #immunemediateddisease #inflammation #drugdiscovery #biochemicalassays #ADPGlo #fluorescencepolarization #FP #functionalassays #therapeuticresearch #drugscreening #immunology

What's the theme of this week's poster review for 2024? Let's revisit one of the posters we presented at AAPS 2024! It focuses on advancing targeted therapies for HR+/HER2- breast cancer, a subtype that remains one of the leading causes of cancer-related deaths worldwide. HR+/HER2- breast cancer is the most common subtype, accounting for 69% of all breast cancer cases worldwide. CDK4/6 inhibitors, when combined with endocrine therapy, currently represent the standard-of-care for advanced stages of the disease. However, resistance to CDK4/6 inhibitors remains a significant challenge. To address this challenge, our research targets novel CDK family members to identify inhibitors that can overcome resistance to CDK4/6 inhibitors. These inhibitors, alone or in combination, show strong potential for bypassing resistance. Many companies, including Avenzo Therapeutics, Carrick Therapeutics, and Iambic Therapeutics are advancing their drug development pipelines in this direction. Using advanced assays and innovative technologies, we’ve developed a series of in vitro and in vivoassays, enabling high-throughput screening and a more efficient strategy for identifying effective CDK inhibitors. In our efforts, we have: ✅ Optimized insect expression systems to measure kinase activity for CDK family targets (CDK2, CDK4, CDK6, CDK7). ✅ Enhanced enzymatic and cell-based assays for the CDK family, including the ADP-Glo assay, NanoBRET target engagement assay, and BaF3 cell viability assays. ✅ Developed stable drug-resistant cell lines to test inhibitors under resistance conditions. ✅ Utilized AlphaLISA assays, flow cytometry, and Simple Western (Jess™) analyses to assess the effects of inhibitors on cell signaling and cell cycle progression. ✅ Created multiple CDX models using human breast cancer cell lines Explore our latest posters here.👉 https://lnkd.in/ghjY8K_v #BreastCancer #CDK #CDKInhibitors #CancerResearch #DrugDiscovery #Oncology #Pharmaceutical #AAPS2024 #CellProliferation #PhosphorylationAnalysis #CDXModel

cGAS and STING are critical regulators of immune responses, playing key roles in intracellular DNA sensing and the induction of type I interferons and inflammatory mediators. Dysregulation of the cGAS-STING pathway is associated with autoimmune diseases, inflammation, and cancer, making it a promising target for therapeutic development. A growing number of companies, such as IFM Therapeutics, ImmuneSensor Therapeutics, and Mersana Therapeutics, are advancing the discovery of modulators for the cGAS-STING pathway, focusing on both activators and inhibitors to address these conditions. 🔸 cGAS Antagonist/Agonist Reporter Assay: Measures luminescence to evaluate cGAS pathway modulators. 🔸 STING Agonist/Antagonist Reporter Assay: Measures STING pathway activation or inhibition, facilitating screening for immune modulators. 🔸 Cytokine Release Assays: Quantifies IFN-β production in immune cells, highlighting immune activation and inhibition. 🔸 Western Blot and Jess Automated Western Assay: Detects key biomarkers like STING oligomerization, pSTING, pTBK1, and pIRF3, providing molecular insights into pathway activation. Explore how our cutting-edge platforms can support your research into cGAS-STING modulators and therapeutic strategies 👉 https://lnkd.in/gdvNnN42 #cGAS #STING #Immunology #DrugDiscovery #CytokineRelease #WesternBlot #CellBasedAssays #Biotech #Therapeutics

🎬 Lights, camera… action! Something exciting is happening behind the scenes at ICE Bioscience! Here’s a sneak peek from today’s shoot—can you guess what we’re up to? 🤔 (Hint: It’s about telling our story in a way we’ve never done before!) Stay tuned for the big reveal! #BehindTheScenes #ExcitingTimes #StayTuned

As part of our ongoing year-end review series, we’re excited to share the third installment this week, highlighting one of the posters we presented at DOT 2024. The poster showcases our Biology Building Blocks platform, focused on developing and applying assays for anti-obesity targets. Obesity has become a global public health issue over the past 50 years, impacting quality of life, increasing disease risks, and raising healthcare costs worldwide. Our platform is designed to address this need, targeting key obesity-related receptors, including #CB1, #APJ, and #GPR75, each of which plays a role in the anti-obesity pathway through different mechanisms. Inversago Pharma, Anebulo Pharmaceuticals, Corbus Pharmaceuticals, APIE Therapeutics, Confometrx, Inc, and Confo Therapeutics have been actively involved in research related to these targets, advancing the understanding and potential therapies for obesity. Using advanced technologies, we’ve been able to: ✅Develop and validate assays for anti-obesity targets, including CB1, APJ, and GPR75 ✅Generate stable GPCR overexpression cell lines for high-throughput screening and functional assays ✅Utilize advanced technologies such as HTRF cAMP assays, β-Arrestin NanoBiT assays, and SPR-based biophysical assays to screen and characterize drug interactions ✅Conduct in vivo validation using high fat diet induced obese (DIO) mouse models to assess drug efficacy Explore our latest posters here.👉https://lnkd.in/g32CeZHb #AntiObesity #DrugDiscovery #GPCR #Biotech #PharmaceuticalResearch #ObesityResearch #HTRFCAMP #NanoBiT #SPR #InnovativeResearch #BiologyBuildingBlocks #DOT2024

NLRP3 and NEK7 are critical regulators of immune responses and inflammation, with dysregulation leading to a range of inflammatory diseases. Investigating the interactions between NLRP3 and NEK7 is essential for developing targeted therapies for these conditions. At present, a number of companies are advancing the development of targeted inhibitors for key immune regulators. NodThera, Ventyx Biosciences, and Ventus Therapeutics are leading efforts to develop compounds targeting NLRP3. Halia Therapeutics, Inc., Captor Therapeutics SA, and Monte Rosa Therapeutics are focused on NEK7 inhibitors. ICE Bioscience offers a comprehensive suite of assays to support drug discovery efforts focused on NLRP3 and NEK7, providing insights into their activation, interaction, and regulatory mechanisms. 🔸 NLRP3 ADP-Glo Assay: Assesses NLRP3 ATP hydrolysis activity, providing insights into its activation and the effects of inhibitors.  🔸 NEK7 ADP-Glo Assay: Assesses NEK7 catalytic activity, crucial for understanding its role in NLRP3 activation.  🔸 NLRP3 & NEK7 HTRF Assay: Monitors the binding interaction between NLRP3 and NEK7 using FRET, allowing for drug screening of inflammasome modulators.  🔸 Cell-Based Assay: Evaluates the impact of NEK7 inhibition on NLRP3 activation, cytokine release, and cell viability in relevant cellular models. Explore how our assays can enhance your research into NLRP3 and NEK7 as therapeutic targets 👉 https://lnkd.in/gcaQU8-u #NLRP3 #NEK7 #Inflammation #DrugDiscovery #BiochemicalAssays #HTRF #ADPGlo #CellBasedAssay #TherapeuticResearch #Biotech #DrugScreening  #Immunology

To continue our series of year-end reviews, this week we present the second installment, which features one of the posters we presented at ISSX/JSSX 2024. The poster showcases the development of a rapid kinetic analysis platform for irreversible covalent inhibitors using Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS). Targeted covalent inhibitors have emerged as a powerful tool in drug discovery, but their development has been hindered by challenges in accurately assessing their kinetics and binding interactions. To address this, we created a platform that enables direct detection of native proteins and covalent adducts, helping to accelerate the discovery and optimization of covalent-based therapeutics. Using LC-HRMS technology, we’ve been able to: ✅ Screen covalent inhibitors with unprecedented sensitivity and accuracy ✅ Characterize binding sites and determine occupancy rates with intact protein and peptide mapping ✅ Measure critical kinetic parameters like Kinact/Ki, providing deeper insights into target engagement Explore our latest posters here.👉https://lnkd.in/gAyFbfm5 #CovalentInhibitors #ISSX2024 #JSSX2024 #MassSpectrometry #DrugDiscovery #PharmaceuticalResearch #Biotech #Oncology #KineticAnalysis #InnovativeResearch #LCMS #LCHRMS